BioNTech SE/$BNTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

Ticker

$BNTX
Primary listing

Industry

Biotechnology
Headquarters

Employees

6,772

ISIN

US09075V1026

BioNTech SE Metrics

BasicAdvanced
$25B
-
-$3.67
1.36
-

What the Analysts think about BioNTech SE

Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.

Bulls say / Bears say

BioNTech's partnership with Bristol Myers Squibb, involving a $1.5 billion upfront payment to co-develop the experimental cancer drug BNT327, signifies strong confidence in BioNTech's oncology pipeline and potential future revenue streams. (reuters.com)
The acquisition of Biotheus for $800 million grants BioNTech full global rights to BNT327/PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, enhancing its oncology portfolio and expanding its presence in the Chinese market. (stocktitan.net)
Analyst sentiment remains positive, with multiple 'Buy' ratings and an average 12-month price target of $131.75, indicating confidence in BioNTech's growth prospects. (markets.businessinsider.com)
BioNTech reported its first loss since 2020 due to a significant decline in COVID-19 vaccine demand, raising concerns about its ability to maintain profitability as pandemic-related revenues decrease. (bloomberg.com)
The FDA's appointment of Dr. Vinay Prasad, a known critic of COVID-19 policies, to head its Center for Biologics Evaluation and Research has introduced regulatory uncertainties that could impact BioNTech's vaccine approvals and market performance. (finviz.com)
BioNTech's Q3 2024 financial results showed a downgrade in COVID-19 vaccine revenue guidance, suggesting potential challenges in sustaining revenue levels as the pandemic subsides. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.

BioNTech SE Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BioNTech SE Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BNTX

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs